determined almost instantly through a comparison of a unique electronic signature generated from contact of the solution with a disposable BIOMEMS sensor chip and comparison to a known library of profiles. SEA's technology is broadly applicable to multiple platforms including preventing IV preparation errors in the Pharmacy, identifying and stopping medication errors at the bedside, keeping expensive biopharmaceutical manufacturing on track, ensuring dialysis patients get their full therapeutic benefit, and detecting counterfeit medications to prevent them from entering the distribution channel. These devices cumulatively have the real potential for multi-billion dollar annual product sales. For example, Auto IV is a disruptive technology that has the potential to revolutionize the smart pump business, currently valued at over $3B per year in the US. Companies in these business segments find our technology compelling and for the right investor or partner, this is an opportunity to have a major transformative impact on Medicine. Based in San Jose, CA, the company has been supported by Series A investors including Quantum Technology Partners, New Biology Ventures, and private investors, Series B investor JK&B Capital and non-dilutive capital.